BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 14645590)

  • 1. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.
    Vogel TU; Reynolds MR; Fuller DH; Vielhuber K; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Marthas ML; Erfle V; Wolinsky SM; Wang C; Allison DB; Rud EW; Wilson N; Montefiori D; Altman JD; Watkins DI
    J Virol; 2003 Dec; 77(24):13348-60. PubMed ID: 14645590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.
    Horton H; Vogel TU; Carter DK; Vielhuber K; Fuller DH; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Montefiori DC; Erfle V; Desrosiers RC; Wilson N; Picker LJ; Wolinsky SM; Wang C; Allison DB; Watkins DI
    J Virol; 2002 Jul; 76(14):7187-202. PubMed ID: 12072518
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Martins MA; Tully DC; Pedreño-Lopez N; von Bredow B; Pauthner MG; Shin YC; Yuan M; Lima NS; Bean DJ; Gonzalez-Nieto L; Domingues A; Gutman MJ; Maxwell HS; Magnani DM; Ricciardi MJ; Bailey VK; Altman JD; Burton DR; Ejima K; Allison DB; Evans DT; Rakasz EG; Parks CL; Bonaldo MC; Capuano S; Lifson JD; Desrosiers RC; Allen TM; Watkins DI
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques.
    McDermott AB; O'Connor DH; Fuenger S; Piaskowski S; Martin S; Loffredo J; Reynolds M; Reed J; Furlott J; Jacoby T; Riek C; Dodds E; Krebs K; Davies ME; Schleif WA; Casimiro DR; Shiver JW; Watkins DI
    J Virol; 2005 Dec; 79(24):15556-66. PubMed ID: 16306626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.
    Barouch DH; Santra S; Kuroda MJ; Schmitz JE; Plishka R; Buckler-White A; Gaitan AE; Zin R; Nam JH; Wyatt LS; Lifton MA; Nickerson CE; Moss B; Montefiori DC; Hirsch VM; Letvin NL
    J Virol; 2001 Jun; 75(11):5151-8. PubMed ID: 11333896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system.
    Evans DT; Chen LM; Gillis J; Lin KC; Harty B; Mazzara GP; Donis RO; Mansfield KG; Lifson JD; Desrosiers RC; Galán JE; Johnson RP
    J Virol; 2003 Feb; 77(4):2400-9. PubMed ID: 12551977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
    Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
    Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
    Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
    J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Frequency of Vaccine-Induced T-Cell Responses Does Not Predict the Rate of Acquisition after Repeated Intrarectal SIVmac239 Challenges in
    Martins MA; Gonzalez-Nieto L; Shin YC; Domingues A; Gutman MJ; Maxwell HS; Magnani DM; Ricciardi MJ; Pedreño-Lopez N; Bailey VK; Altman JD; Parks CL; Allison DB; Ejima K; Rakasz EG; Capuano S; Desrosiers RC; Lifson JD; Watkins DI
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.
    Doria-Rose NA; Ohlen C; Polacino P; Pierce CC; Hensel MT; Kuller L; Mulvania T; Anderson D; Greenberg PD; Hu SL; Haigwood NL
    J Virol; 2003 Nov; 77(21):11563-77. PubMed ID: 14557642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.
    Egan MA; Charini WA; Kuroda MJ; Schmitz JE; Racz P; Tenner-Racz K; Manson K; Wyand M; Lifton MA; Nickerson CE; Fu T; Shiver JW; Letvin NL
    J Virol; 2000 Aug; 74(16):7485-95. PubMed ID: 10906202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses.
    Abel K; Compton L; Rourke T; Montefiori D; Lu D; Rothaeusler K; Fritts L; Bost K; Miller CJ
    J Virol; 2003 Mar; 77(5):3099-118. PubMed ID: 12584336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.
    Allen TM; Mortara L; Mothé BR; Liebl M; Jing P; Calore B; Piekarczyk M; Ruddersdorf R; O'Connor DH; Wang X; Wang C; Allison DB; Altman JD; Sette A; Desrosiers RC; Sutter G; Watkins DI
    J Virol; 2002 Apr; 76(8):4108-12. PubMed ID: 11907251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.
    Amara RR; Smith JM; Staprans SI; Montefiori DC; Villinger F; Altman JD; O'Neil SP; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McNicholl JM; McClure HM; Moss B; Robinson HL
    J Virol; 2002 Jun; 76(12):6138-46. PubMed ID: 12021347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.
    Bertley FM; Kozlowski PA; Wang SW; Chappelle J; Patel J; Sonuyi O; Mazzara G; Montefiori D; Carville A; Mansfield KG; Aldovini A
    J Immunol; 2004 Mar; 172(6):3745-57. PubMed ID: 15004179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine-based, long-term, stable control of simian/human immunodeficiency virus 89.6PD replication in rhesus macaques.
    Yamamoto H; Kawada M; Tsukamoto T; Takeda A; Igarashi H; Miyazawa M; Naruse T; Yasunami M; Kimura A; Matano T
    J Gen Virol; 2007 Feb; 88(Pt 2):652-659. PubMed ID: 17251584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine.
    Fuller DH; Rajakumar PA; Wilson LA; Trichel AM; Fuller JT; Shipley T; Wu MS; Weis K; Rinaldo CR; Haynes JR; Murphey-Corb M
    J Virol; 2002 Apr; 76(7):3309-17. PubMed ID: 11884556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
    Matano T; Kobayashi M; Igarashi H; Takeda A; Nakamura H; Kano M; Sugimoto C; Mori K; Iida A; Hirata T; Hasegawa M; Yuasa T; Miyazawa M; Takahashi Y; Yasunami M; Kimura A; O'Connor DH; Watkins DI; Nagai Y
    J Exp Med; 2004 Jun; 199(12):1709-18. PubMed ID: 15210746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.